• Featured Product
  • KD/KO Validated

CD47 Polyclonal antibody

CD47 Polyclonal Antibody for IHC, ELISA

Host / Isotype

Rabbit / IgG


human and More (1)





Cat no : 20305-1-AP


CD47, CD47 molecule, IAP, Leukocyte surface antigen CD47, MER6, OA3, Protein MER6

Tested Applications

Positive IHC detected inhuman prostate cancer tissue, human ovary tumor tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Immunohistochemistry (IHC)IHC : 1:500-1:2000
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 20305-1-AP is CD47 Fusion Protein expressed in E. coli.

Tested Reactivity human
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen CD47 fusion protein Ag14132
Full Name CD47 molecule
Calculated molecular weight 323 aa, 35 kDa
GenBank accession numberBC010016
Gene symbol CD47
Gene ID (NCBI) 961
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

CD47, also known as integrin-associated protein (IAP), is a member of the immunoglobulin superfamily containing a five-pass transmembrane attachment. CD47 is heavily glycosylated and widely expressed by hematopoietic and nonhematopoietic cells. CD47 interacts with several membrane integrins and also acts a receptor for thrombospondin (THBS1). It is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. CD47 also functions as a ligand for signal regulatory protein-α (SIRPα). Upon binding CD47, SIRPα initiates a signaling cascade that results in the inhibition of phagocytosis.


Product Specific Protocols
IHC protocol for CD47 antibody 20305-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols




Bioengineering CXCR4-overexpressing cell membrane functionalized ROS-responsive nanotherapeutics for targeting cerebral ischemia-reperfusion injury.

Authors - Li Luo

ACS Appl Mater Interfaces

PMID: 31718159

Authors - Tengfei Wang

J Control Release

Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor

Authors - Haoyu Guo

Front Cell Dev Biol

Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis.

Authors - Qianfu Zhao

J Cell Commun Signal

CD47 interactions with exportin-1 limit the targeting of m 7 G-modified RNAs to extracellular vesicles

Authors - Sukhbir Kaur
  • KD Validated

J Cancer Res Clin Oncol

Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.

Authors - Fangqiu Fu